Drug intelligence / Profile preview

WGc-0901

Development stage: Preclinical
Lead developer: Chengdu Weisijin Biopharmaceutical Technology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

WGc-0901 is a preclinical mRNA-based tumor vaccine candidate developed by WestGene for the treatment of solid tumors. As part of WestGene's tumor treatment vaccine platform, the drug utilizes mRNA technology to induce anti-tumor immune responses. While the specific antigen targets have not been disclosed, the vaccine is intended to stimulate the immune system to recognize and eliminate malignant cells in various solid tumor types.

Beyond the preview

Go deeper on WGc-0901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WGc-0901.

Explore the full profile